Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 2,500 shares of Lexeo Therapeutics stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $8.20, for a total transaction of $20,500.00. Following the completion of the sale, the chief executive officer now directly owns 120,695 shares of the company's stock, valued at $989,699. The trade was a 2.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Richard Nolan Townsend also recently made the following trade(s):
- On Monday, November 11th, Richard Nolan Townsend sold 2,500 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $7.82, for a total value of $19,550.00.
- On Thursday, October 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $8.10, for a total transaction of $40,500.00.
Lexeo Therapeutics Stock Down 6.6 %
Shares of NASDAQ:LXEO opened at $7.13 on Friday. The company has a market capitalization of $235.76 million and a price-to-earnings ratio of -2.26. The company has a 50 day moving average of $8.17 and a two-hundred day moving average of $11.39. Lexeo Therapeutics, Inc. has a 52-week low of $5.77 and a 52-week high of $22.33. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.
Institutional Investors Weigh In On Lexeo Therapeutics
Man Who Called Nvidia Says: “Your Retirement Is Inside This Building.”
From Brownstone Research | Ad
In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents.
The company just became the world's third $3 trillion company...
And the stock is up massively since Jeff's recommendation.
Now, Jeff has found five under-the-radar stocks which could power your retirement.
Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its position in Lexeo Therapeutics by 18.9% in the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company's stock valued at $33,997,000 after buying an additional 599,203 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in shares of Lexeo Therapeutics in the third quarter worth about $11,307,000. Vestal Point Capital LP boosted its holdings in Lexeo Therapeutics by 1.2% in the third quarter. Vestal Point Capital LP now owns 850,000 shares of the company's stock valued at $7,684,000 after purchasing an additional 10,000 shares during the last quarter. Verition Fund Management LLC grew its stake in Lexeo Therapeutics by 84.5% during the 3rd quarter. Verition Fund Management LLC now owns 777,320 shares of the company's stock valued at $7,027,000 after purchasing an additional 355,928 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Lexeo Therapeutics by 86.5% during the 3rd quarter. Geode Capital Management LLC now owns 553,247 shares of the company's stock worth $5,003,000 after purchasing an additional 256,635 shares during the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
LXEO has been the topic of several research reports. Leerink Partners cut their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 13th. HC Wainwright lifted their price objective on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a research note on Thursday, November 14th. Finally, Chardan Capital increased their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Lexeo Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $23.80.
Read Our Latest Analysis on Lexeo Therapeutics
Lexeo Therapeutics Company Profile
(
Get Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
